The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-23 and is reviewed periodically as new material appears.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
The ASA is closely related to the concept of the solvent-excluded surface (also known as the Connolly's molecular surface area or simply Connolly surface), which is imagined as a cavity in bulk solvent. It is also calculated in practice via a rolling-ball algorithm developed by Frederic Richards and implemented three-dimensionally by Michael Connolly in 1983 and Tim Richmond in 1984. Connolly spent several more years perfecting the method. Implicit solvation Van der Waals surface VADAR tool for analyzing peptide and protein structures Relative accessible surface area
There is not enough evidence to support the routine use of tranexamic acid to prevent bleeding in people with blood cancers. However, several trials are currently assessing this use of tranexamic acid. For people with inherited bleeding disorders (e.g. von Willebrand's disease), tranexamic acid is often given. It has also been recommended for people with acquired bleeding disorders (e.g., directly acting oral anticoagulants (DOACs)) to treat serious bleeding. The use of tranexamic acid, applied directly to the area that is bleeding or taken by mouth, appears useful to treat nose bleeding compared to packing the nose with cotton pledgets alone. It decreases the risk of rebleeding within 10 days.
As of 2025, only limited human clinical data on D-ribose-L-cysteine have been published. A small randomized, placebo-controlled pilot trial conducted in 2023 evaluated the effect of a D-ribose-L-cysteine-containing supplement on serum glutathione levels in healthy adults over a 28-day period. According to results released by the study sponsor, participants receiving D-ribose-L-cysteine experienced a statistically significant increase in serum glutathione relative to baseline, with larger increases observed in older participants. The trial has not yet been independently replicated, and full peer-reviewed publication of the data has not been confirmed. Accordingly, the clinical significance of these findings remains preliminary.
GLD-2 (which stands for Germ Line Development 2) is an enzyme which in humans is encoded by the gene TENT2. More specifically, it is a cytoplasmic poly(A) polymerase (cytoPAPs) which adds successive AMP monomers to the 3’ end of specific RNAs, forming a poly(A) tail, which is a process known as polyadenylation. For RNA specificity, GLD-2 associates with an RNA-binding protein, typically a GLD-3, to form a heterodimer that acts as a cytoplasmic PAP. This protein has an enzymatic function and belongs to a family (DNA polymerase type-B-like family) which includes several similar enzymes such as GLD-1, GLD-3 and GLD-4. This family of cytoplasmic PAPs has been described in several different species including Homo sapiens, Caenorhabditis elegans, Xenopus, Mus musculus and Drosophila. Moreover, as it is a cytoplasmtaic PAP it differs from nuclear PAPs in some aspects. While nuclear PAPs contain a catalytic domain and an RNA-binding domain, GLD-2 family members have only a catalytic domain.
Sources: en.wikipedia.org
== Other animals == Most mammals normally cease to produce lactase and become lactose intolerant after weaning. The downregulation of lactase expression in mice could be attributed to the accumulation of DNA methylation in the Lct gene and the adjacent Mcm6 gene.
First Division (level 2) Runners-up: 1996–97 Third Division North / Third Division / League One (level 3) Champions: 1933–34, 1938–39, 1954–55 Runners-up: 1980–81, 2018–19 Play-off winners: 2006, 2016 Fourth Division (level 4) 2nd place promotion: 1967–68 4th place promotion: 1978–79 Cup
=== Medical food === Glutamine is marketed as medical food and is prescribed when a medical professional believes a person in their care needs supplementary glutamine due to metabolic demands beyond what can be met by endogenous synthesis or diet.
Sources: en.wikipedia.org
Up until his death in 1953, Joseph Stalin controlled all foreign relations of the Soviet Union during the interwar period. Despite the increasing build-up of Germany's war machine and the outbreak of the Second Sino-Japanese War, the Soviet Union did not cooperate with any other nation, choosing to follow its own path. However, after Operation Barbarossa, the Soviet Union's priorities changed. Despite previous conflict with the United Kingdom, Vyacheslav Molotov dropped his post war border demands.
There are few native natural predators of adult emus still extant. Early in its species history it may have faced numerous terrestrial predators now extinct, including the giant lizard Megalania, the thylacine, and possibly other carnivorous marsupials, which may explain their seemingly well-developed ability to defend themselves from terrestrial predators. The main predator of emus today is the dingo, which was originally introduced by Aboriginals thousands of years ago from a stock of semi-domesticated wolves. Dingoes try to kill the emu by attacking the head. The emu typically tries to repel the dingo by jumping into the air and kicking or stamping the dingo on its way down. The emu jumps as the dingo barely has the capacity to jump high enough to threaten its neck, so a correctly timed leap to coincide with the dingo's lunge can keep its head and neck out of danger. Despite the potential prey-predator relationship, the presence of predaceous dingoes does not appear to heavily influence emu numbers, with other natural conditions just as likely to cause mortality. Wedge-tailed eagles are the only avian predator capable of attacking fully-grown emus, though are perhaps most likely to take small or young specimens. The eagles attack emus by swooping downwards rapidly and at high speed and aiming for the head and neck. In this case, the emu's jumping technique as employed against the dingo is not useful. The birds try to target the emu in the open ground so that it cannot hide behind obstacles.
Motorsport Space travel Sports equipment Sailing Orthopedic technology in orthotics as well as in prosthetics In electrical engineering as an "intermediate layer" in multilayer circuit boards and as insulating material for electrical machines and transformers Rotor blades in wind turbines
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.